Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paula L McClean

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Neuropharmacology|August 10, 2014
Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's diseasePaula L McClean, Christian Hölscher
Neural Regeneration Research|August 24, 2018
Distinguishing normal brain aging from the development of Alzheimer's disease: inflammation, insulin signaling and cognitionPaul Denver, Paula L McClean
Neuropharmacology|August 27, 2013
Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's diseasePaula L McClean, Christian Hölscher
Behavioural Brain Research|July 25, 2015
Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 micePaula L McClean, Jaishree Jalewa, Christian Hölscher
Brain, Behavior, and Immunity|April 1, 2018
Inflammation, insulin signaling and cognitive function in aged APP/PS1 micePaul Denver, Andrew English, Paula L McClean
Journal of Peptide Science : an Official Publication of the European Peptide Society|May 9, 2007
Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) miceNigel Irwin, Paula L McClean, Peter R Flatt
Diabetes, Obesity & Metabolism|January 10, 2018
Sustained high-fat diet modulates inflammation, insulin signalling and cognition in mice and a modified xenin peptide ameliorates neuropathology in a chronic high-fat modelPaul Denver, Victor A Gault, Paula L McClean
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|April 29, 2011
The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's diseasePaula L McClean, Vadivel Parthsarathy, Emilie Faivre, et al.
Medicines (Basel, Switzerland)|September 6, 2019
Early Stage Glycosylation Biomarkers in Alzheimer's DiseasePatricia Regan, Paula L McClean, Thomas Smyth, et al.
Experimental Gerontology|December 23, 2006
Beneficial effects of sub-chronic activation of glucagon-like peptide-1 (GLP-1) receptors on deterioration of glucose homeostasis and insulin secretion in aging miceNigel Irwin, Paula L McClean, Patrick Harriott, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Neuropharmacology|August 10, 2014
Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's diseasePaula L McClean, Christian Hölscher
Neural Regeneration Research|August 24, 2018
Distinguishing normal brain aging from the development of Alzheimer's disease: inflammation, insulin signaling and cognitionPaul Denver, Paula L McClean
Neuropharmacology|August 27, 2013
Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's diseasePaula L McClean, Christian Hölscher
Behavioural Brain Research|July 25, 2015
Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 micePaula L McClean, Jaishree Jalewa, Christian Hölscher
Brain, Behavior, and Immunity|April 1, 2018
Inflammation, insulin signaling and cognitive function in aged APP/PS1 micePaul Denver, Andrew English, Paula L McClean
Journal of Peptide Science : an Official Publication of the European Peptide Society|May 9, 2007
Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) miceNigel Irwin, Paula L McClean, Peter R Flatt
Diabetes, Obesity & Metabolism|January 10, 2018
Sustained high-fat diet modulates inflammation, insulin signalling and cognition in mice and a modified xenin peptide ameliorates neuropathology in a chronic high-fat modelPaul Denver, Victor A Gault, Paula L McClean
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|April 29, 2011
The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's diseasePaula L McClean, Vadivel Parthsarathy, Emilie Faivre, et al.
Medicines (Basel, Switzerland)|September 6, 2019
Early Stage Glycosylation Biomarkers in Alzheimer's DiseasePatricia Regan, Paula L McClean, Thomas Smyth, et al.
Experimental Gerontology|December 23, 2006
Beneficial effects of sub-chronic activation of glucagon-like peptide-1 (GLP-1) receptors on deterioration of glucose homeostasis and insulin secretion in aging miceNigel Irwin, Paula L McClean, Patrick Harriott, et al.
Pageof 5